Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price traded up 20.7% on Thursday . The stock traded as high as C$0.24 and last traded at C$0.18. 691,700 shares traded hands during mid-day trading, an increase of 54% from the average session volume of 450,083 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Up 31.0 %
The stock has a market capitalization of C$16.55 million, a price-to-earnings ratio of -9.50 and a beta of 0.20. The business’s 50-day moving average is C$0.09 and its two-hundred day moving average is C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What Makes a Stock a Good Dividend Stock?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- What is the S&P/TSX Index?
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Stock Market Upgrades: What Are They?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
